Maxhn McCaw, DO
General Practice · Orion, ILNPI 1275511305
Payments from drug & device makers
Across 176 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$894
- AstraZeneca$598
- Otsuka America Pharmaceutical, Inc.$165
- Biohaven Pharmaceutical Holding Company Ltd.$132
- Johnson & Johnson$121
- GSK$94
- plus $648 from 15 others
What the payments were for
- Food & beverage$2,653100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $894 |
| AstraZeneca | 34 | $598 |
| Otsuka America Pharmaceutical, Inc. | 10 | $165 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $132 |
| Johnson & Johnson | 8 | $121 |
| GSK | 6 | $94 |
| Nestle Healthcare Nutrition Inc. | 6 | $92 |
| Pfizer | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 5 | $71 |
| Novartis | 5 | $71 |
| Aimmune Therapeutics, Inc. | 4 | $70 |
| Novo Nordisk | 4 | $58 |
| Amgen | 4 | $55 |
| Esperion Therapeutics, Inc. | 3 | $36 |
| Abbott | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
How this compares
$2,653 in reported general payments places this provider in the 90th percentile of 3,816 general practice providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $55,503 |
| FarxigaDapagliflozin Propanediol | 55 | $40,801 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $39,332 |
| OzempicSemaglutide | 29 | $31,019 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $24,488 |
| XareltoRivaroxaban | 30 | $19,668 |
| JardianceEmpagliflozin | 13 | $10,502 |
| EntrestoSacubitril/Valsartan | 13 | $8,378 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,501 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $5,374 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,575 |
| ZenpepLipase/Protease/Amylase | 11 | $4,121 |
| MyrbetriqMirabegron | 12 | $3,933 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,856 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $2,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $598 | $70,79097 claims |
| PfizerEliquis | $80 | $55,50382 claims |
| GSKTrelegy Ellipta | $94 | $39,33248 claims |
| Novo NordiskOzempic | $58 | $31,01929 claims |
| Johnson & JohnsonXarelto | $121 | $19,66830 claims |
| Boehringer IngelheimJardiance | $15 | $10,50213 claims |
| NovartisEntresto | $71 | $8,37813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $13 | $4,57512 claims |
| Aimmune Therapeutics, Inc.Zenpep | $70 | $4,12111 claims |
| AbbVieSynthroid | $894 | $2,23422 claims |
| Lilly USA, LLCHumalog | $19 | $83812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,816 general practice providers in Illinois.
Other general practice in Orion
- Ryan MolisBurr Ridge$13M
- Ronald StumbrisPalos Heights$3.8M
- Lou GrahamChicago$603K
- Kenya ThomasChicago$595K
- Brijesh PatelSchaumburg$547K
- Alan BoghosianChicago$349K
- Anthony PonzioElmwood Park$253K
- Dennis HartliebGlenview$160K
- Miguel NayanWestmont$149K
- Peter HarnoisHinsdale$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.